Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a phase I clinical trial.
Saved in:
| Title: | Allogeneic CD56 + cell infusion as a bridge to hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a phase I clinical trial. |
|---|---|
| Authors: | Ghasabeh AS; Laboratory Hematology and Blood Bank Department, School of Allied Medical Science, Shahid Beheshti University of Medical Science, Tehran, Iran., Izadpanah A; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Bakhtiyaridovvombaygi M; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.; Student Research Committee, Laboratory Hematology and Blood Bank Department, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Seresht-Ahmadi M; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Parkhideh S; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Seraji HR; Department of Hematology and Oncology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Sabri A; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Yazdanparast S; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Hajifathali A; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. hajifathali@yahoo.com., Gharehbaghian A; Laboratory Hematology and Blood Bank Department, School of Allied Medical Science, Shahid Beheshti University of Medical Science, Tehran, Iran. gharehbaghian@hotmail.com., Roshandel E; Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. elham.roshandel@gmail.com. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Mar 31; Vol. 75 (4). Date of Electronic Publication: 2026 Mar 31. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
